Inpharma Weekly

, Volume 1015, Issue 1, pp 9–10 | Cite as

New antifungal agents needed for immunocompromised patients

  • Helen Mellsop
Newsletter Article


Several pharmaceutical companies worldwide have joined in a race to develop new antifungal agents for patients with compromised immune systems. Prominent at the 35th International Conference on Antimicrobial Agents and Chemotherapy [ San Francisco, US; September 1995 ] were presentations from Pfizer and Schering-Plough on their new azole derivatives UK-109496 and SCH-56592, which are at phase II and preclinical stages of development, respectively.


Fluconazole Itraconazole Candidiasis Azole Aspergillosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1995

Authors and Affiliations

  • Helen Mellsop

There are no affiliations available

Personalised recommendations